Bryant Woods Investment Advisors LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Bryant Woods Investment Advisors LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 10.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,806 shares of the company’s stock after selling 218 shares during the quarter. Bryant Woods Investment Advisors LLC’s holdings in Johnson & Johnson were worth $281,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in JNJ. Alliance Wealth Advisors LLC UT raised its stake in shares of Johnson & Johnson by 1.4% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock valued at $739,000 after purchasing an additional 64 shares in the last quarter. Carolinas Wealth Consulting LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after acquiring an additional 64 shares during the last quarter. Epic Trust Investment Advisors LLC boosted its holdings in Johnson & Johnson by 3.6% in the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock worth $268,000 after purchasing an additional 64 shares during the period. Verity Asset Management Inc. increased its stake in Johnson & Johnson by 2.0% during the fourth quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock valued at $512,000 after purchasing an additional 65 shares during the last quarter. Finally, Forza Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 0.8% during the second quarter. Forza Wealth Management LLC now owns 8,742 shares of the company’s stock worth $1,278,000 after purchasing an additional 66 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $164.13 on Monday. Johnson & Johnson has a one year low of $143.13 and a one year high of $167.78. The business’s 50-day moving average price is $153.92 and its two-hundred day moving average price is $153.20. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market capitalization of $395.01 billion, a P/E ratio of 10.23, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.80 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s payout ratio is presently 30.92%.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. The Goldman Sachs Group dropped their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Cowen cut their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.